Form 4: NeuroOne Medical Technologies CEO Sells Shares to Cover Tax Obligations
SEC Form 4
NeuroOne Medical Technologies CEO, David A. Rosa, sold 2,239 shares of common stock to cover tax obligations.
Summary
- David A. Rosa, the CEO and President of NeuroOne Medical Technologies, sold 2,239 shares of common stock on November 30, 2024.
- The shares were sold at a price of $0.6231 per share.
- This transaction was to cover tax obligations.
- Following the transaction, Mr. Rosa directly owns 1,142,008 shares of NeuroOne Medical Technologies common stock.
Sentiment
Score: 5
Explanation: The document describes a routine transaction for tax purposes, which is neither positive nor negative for the company's outlook.
Industry Context
This is a routine transaction for executives to manage their personal finances and tax obligations. It is not unusual for executives to sell shares to cover taxes.
Comparison to Industry Standards
- Executive stock sales for tax purposes are common across the industry.
- The sale of 2,239 shares is a relatively small transaction compared to the total holdings of 1,142,008 shares, suggesting it is not a significant divestment.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on shareholders, employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 11/30/2024 | Date of the stock sale transaction. |
| 12/03/2024 | Date the form was signed. |
Keywords
NeuroOne Medical Technologies, David A. Rosa, stock sale, insider trading, tax obligations, CEO, NMTC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.